Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Contract Research & Services
Clinical Trials
Return to: PBR Home | Contract Research & Services | Clinical Trials

Clinical Trials

Theratechnologies unveils completion of enrollment for phase III Ibalizumab trial Theratechnologies has been notified by its partner, TaiMed Biologics, Inc., that the enrollment for the Phase III study of ibalizumab, in combination with optimized background regimen (patients' current therapy), for patients infected with multi-drug resistant HIV-1 has been completed as of April 27, 2016.
Contract Research & Services > Clinical Trials > News
Alkermes plans to start second clinical trial of ALKS 7119 Alkermes announced preliminary findings from a phase 1 clinical trial of ALKS 7119, an oral, novel small molecule that acts on multiple key receptor systems in the brain
Contract Research & Services > Clinical Trials > News Celldex starts phase 1/2 study of glembatumumab vedotin in squamous cell lung cancer By PBR Staff Writer
Celldex Therapeutics has started a phase 1/2 study of its antibody-drug conjugate, glembatumumab vedotin, in squamous cell lung cancer.
Contract Research & Services > Clinical Trials > News
See more Clinical Trials news

Latest Clinical Trials News and Insight

View all Clinical Trials news or find news targeted to your interests
Pfizer completes patient enrollment in bococizumab SPIRE-2 cardiovascular outcome trial
Pfizer has completed patient enrollment in the global SPIRE-2 cardiovascular outcome trial for its investigational agent bococizumab.
Contract Research & Services > Clinical Trials > News
Worldwide Clinical Trials opens new site in St. Petersburg, Russia
Worldwide Clinical Trials has opened a new, larger depot site in St. Petersburg, Russia.
Contract Research & Services > Clinical Trials > News
BioMarin enrolls first patient in phase 1/2 trial of NAGLU Fusion Protein BMN 250 to treat MPS IIIB
BioMarin Pharmaceutical has enrolled the first patient in a Phase 1/2 trial for BMN 250, an investigational enzyme replacement therapy using a novel fusion of recombinant human alpha-N-acetyglucosaminidase (NAGLU) with a peptide derived from insulin-like growth factor 2 (IGF2), for the treatment of Sanfilippo B syndrome or mucopolysaccharidosis IIIB (MPS IIIB).
Contract Research & Services > Clinical Trials > News
Fibrocell announces last patient visit for primary endpoint analysis in phase II trial of azficel-T to treat vocal cord scarring
Fibrocell Science announced that the last patient visit for primary endpoint analysis has been completed in its Phase II clinical trial of azficel-T for the treatment of vocal cord scarring resulting in chronic or severe dysphonia.
Contract Research & Services > Clinical Trials > News
Helix's trial steering committee recommends to start phase II L-DOS47 study in NSCLC
Helix BioPharma announced the recommendation by the Trial Steering Committee to initiate the Phase II component of the LDOS002 study.
Contract Research & Services > Clinical Trials > News
TapImmune to start phase 2 ovarian cancer trial with AstraZeneca's durvalumab
By PBR Staff Writer
TapImmune has unveiled plans to start a phase 2 trial of its TPIV 200 in combination with Astra Zeneca's durvalumab (MEDI4736) monoclonal antibody in patients with platinum-resistant ovarian cancer.
Contract Research & Services > Clinical Trials > News
Novartis' Afinitor drug reduces seizures in tuberous sclerosis complex patients
By PBR Staff Writer
Novartis said its Afinitor (everolimus) drug has significantly reduced treatment-resistant seizures in phase III study of patients with tuberous sclerosis complex (TSC).
Contract Research & Services > Clinical Trials > News
TiGenix selects TFS for first clinical trial to treat severe sepsis with allogeneic expanded adipose-derived stem cells
TiGenix has selected TFS International (TFS) for the first clinical trial (SEPCELL) to use stem cell therapy in the treatment of severe sepsis secondary to severe community acquired pneumonia (sCAP).
Contract Research & Services > Clinical Trials > News
Pfizer says phase 3 trial data supports efficacy of Ibrance breast cancer drug
By PBR Staff Writer
Pfizer said that the phase 3 Paloma-2 trial has provided confirmatory evidence for its Ibrance (palbociclib) in combination with letrozole in the first-line setting in certain patients with breast cancer.
Contract Research & Services > Clinical Trials > News
Gilead unveils results From two phase 3 studies evaluating tenofovir alafenamide for chronic HBV infection
Gilead Sciences announced detailed 48-week results from two large Phase 3 clinical trials (Studies 108 and 110) evaluating once-daily tenofovir alafenamide (TAF) 25 mg in treatment-naïve and treatment-experienced adults with HBeAg-negative and HBeAg-positive chronic hepatitis B virus (HBV) infection.
Contract Research & Services > Clinical Trials > News
View all Clinical Trials news or find news targeted to your interests